Maze Therapeutics Inc (MAZE)

May 14, 2025, 4:01 PM EDT - 5 days ago

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

May 13, 2025, 7:30 AM EDT - 7 days ago

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Mar 31, 2025, 7:30 AM EDT - 7 weeks ago

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Feb 7, 2025, 8:00 AM EST - 3 months ago

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Feb 1, 2025, 2:10 AM EST - 3 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MTSR ODTX ODYS SAIL

Jan 31, 2025, 12:33 PM EST - 3 months ago

Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Jan 30, 2025, 7:45 PM EST - 3 months ago

Biotech firm Maze Therapeutics raises $140 million in US IPO

Jan 30, 2025, 7:30 PM EST - 3 months ago

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Jan 27, 2025, 6:31 AM EST - 4 months ago

Maze Therapeutics targets up to $728 mln valuation in US IPO

Jan 13, 2025, 12:07 PM EST - 4 months ago

Maze Therapeutics Seeks IPO For Trials Ramp-Up

Jan 7, 2025, 6:57 PM EST - 4 months ago

Third Rock-backed Maze Therapeutics reveals profit in US IPO filing

Jan 7, 2025, 5:40 PM EST - 4 months ago

Maze Therapeutics looks for IPO lodestar to guide kidney disease assets through clinical trials

Jan 7, 2025, 4:16 PM EST - 4 months ago

Maze Therapeutics IPO Registration Document (S-1)